| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
198,230,000 |
| Market
Cap: |
32.11(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.162 - $0.162 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapies to treat the whole eye. Co.'s gene therapy candidate includes: OCU400, which is used for the treatment of nuclear receptor subfamily 2 group E member 3 mutation-associated retinal diseases and centrosomal protein 290 mutation-associated retinal diseases; OCU410, which is being developed for the treatment of dry age-related macular degeneration (AMD); OCU200, which is designed to treat diabetic macular edema, diabetic retinopathy and wet AMD; and OCU300, which is a small molecule therapeutic in clinical development for patients with ocular graft-versus-host disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
200,278 |
200,278 |
| Total Buy Value |
$0 |
$0 |
$99,999 |
$99,999 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
724,809 |
| Total Sell Value |
$0 |
$0 |
$0 |
$1,336,737 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Qamar Huma |
Chief Medical OfficerOfficer |
• – – |
2024-03-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,643 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2024-01-03 |
4 |
D |
$0.65 |
$117,673 |
D/D |
(180,204) |
2,009,869 |
|
- |
|
| Upadhyay Arun |
See Remarks |
• – – |
2024-01-03 |
4 |
D |
$0.65 |
$27,186 |
D/D |
(41,633) |
349,589 |
|
- |
|
| Upadhyay Arun |
See Remarks |
• – – |
2023-09-16 |
4 |
D |
$0.41 |
$345 |
D/D |
(842) |
391,222 |
|
- |
|
| Zhang Junge |
Director |
– • – |
2023-06-14 |
4 |
B |
$0.50 |
$99,999 |
I/I |
200,278 |
1,077,182 |
2.1 |
- |
|
| Vu Quan Anh |
CFO/CBOOfficer |
• – – |
2023-03-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
165,934 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2023-02-16 |
4 |
AS |
$1.08 |
$108,000 |
D/D |
(100,000) |
2,190,073 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2023-02-16 |
4 |
OE |
$0.33 |
$33,000 |
D/D |
100,000 |
2,290,073 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2023-01-17 |
4 |
AS |
$1.28 |
$128,000 |
D/D |
(100,000) |
2,227,950 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2023-01-17 |
4 |
OE |
$0.51 |
$51,000 |
D/D |
100,000 |
2,327,950 |
|
- |
|
| Upadhyay Arun |
Chief Scientific Officer |
• – – |
2023-01-03 |
4 |
D |
$1.25 |
$8,878 |
D/D |
(7,102) |
392,981 |
|
- |
|
| Crespo Jessica |
CAO/SVP, Finance |
• – – |
2023-01-03 |
4 |
D |
$1.25 |
$2,391 |
D/D |
(1,913) |
161,478 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2023-01-03 |
4 |
D |
$1.25 |
$47,346 |
D/D |
(37,877) |
2,190,073 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,475,410 |
2,227,950 |
|
- |
|
| Crespo Jessica |
CAO/SVP, Finance |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
122,951 |
163,391 |
|
- |
|
| Upadhyay Arun |
Chief Scientific Officer |
• – – |
2023-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
315,924 |
400,083 |
|
- |
|
| Upadhyay Arun |
Chief Scientific OfficerOffice |
• – – |
2023-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
84,159 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2022-12-16 |
4 |
AS |
$1.43 |
$137,007 |
D/D |
(95,809) |
752,540 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2022-12-16 |
4 |
OE |
$0.51 |
$48,863 |
D/D |
95,809 |
848,349 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2022-10-14 |
4 |
AS |
$1.66 |
$166,000 |
D/D |
(100,000) |
752,540 |
|
- |
|
| Musunuri Shankar |
Chief Executive Officer |
• • – |
2022-10-14 |
4 |
OE |
$0.51 |
$51,000 |
D/D |
100,000 |
852,540 |
|
- |
|
| Kumar Ramesh |
Director |
– • – |
2022-10-06 |
4 |
AS |
$1.83 |
$8,235 |
D/D |
(4,500) |
0 |
|
- |
|
| Kumar Ramesh |
Director |
– • – |
2022-10-06 |
4 |
OE |
$0.51 |
$2,295 |
D/D |
4,500 |
4,500 |
|
- |
|
| Castillo Kirsten |
Director |
– • – |
2022-08-11 |
4 |
S |
$2.91 |
$122,220 |
D/D |
(42,000) |
50,000 |
|
- |
|
| Castillo Kirsten |
Director |
– • – |
2022-08-11 |
4 |
OE |
$0.28 |
$11,760 |
D/D |
42,000 |
92,000 |
|
- |
|
195 Records found
|
|
Page 1 of 8 |
|
|
